David Tiberi

Jun 23, 2023 | mdpi.com | Sara Moore |Paul Wheatley-Price |David Tiberi |Bayan Malakouti-Nejad

Abstract:Concurrent chemoradiotherapy (CRT) is the standard of care for limited-stage small cell lung cancer (LS-SCLC). Local therapy—surgery or stereotactic body radiotherapy (SBRT)—with adjuvant chemotherapy may be appropriate for very early (T1-T2, N0) disease. There is variability in the management of these cases, which may lead to variability in patient outcomes. This study aimed to determine practice patterns for the management of very early LS-SCLC in Canada.